LOGIN  |  REGISTER
Recursion
Cue Biopharma

Agenus to Participate in September Investor Conferences

August 28, 2023 | Last Trade: US$4.18 0.07 -1.65

LEXINGTON, Mass.LEXINGTON, Mass. / Aug 28, 2023 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences:

  • 2023 Wells Fargo Healthcare Conference – Fireside chat presentation will be held in-person on Thursday, September 7th, 2023, at 11:00 a.m. ET in Boston, MA. A live webcast and replay will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.
  • Baird 2023 Global Healthcare Conference– Fireside chat presentation will be held in person on Tuesday, September 12th, 2023, at 4:20 p.m. ET, in New York, NY. This content is for Baird clients attending the conference. There will not be a webcast replay.
  • HC Wainwright 25th Annual Global Investment Conference – Fireside chat presentation will be held in-person on Wednesday, September 13th, 2023, at 11:00 a.m. ET, in New York, NY. A live webcast and replay will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us on LinkedIn and Twitter @agenus_bio.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page